Search results - Portal of Medical Data Models (MDM-Portal)

Filter search results
Select data models

Selected data models

You must log in to select data models for download or further analysis.

373 Search results.

Eligibility Testicular Cancer NCT02276430

- 9/28/21 - 1 form, 3 itemgroups, 11 items, 1 language

Itemgroups: Inclusion Criteria, Additional inclusion criteria for participating in the cardiometabolic risk inventory study, Exclusion Criteria

TACkLE Study - Tackling Adverse Chemotherapy-associated Late Effects; ODM derived from: https://clinicaltrials.gov/show/NCT02276430

Liver and Renal Function After Different Contrast Media NCT01563484 - Eligibility Criteria

- 9/20/21 - 1 form, 2 itemgroups, 10 items, 1 language

Itemgroups: Inclusion Criteria, Exclusion Criteria

Comparison of Liver and Renal Function After Transarterial Chemoembolization for Primary Hepatocellular Carcinoma With Iso-osmolar Contrast Media and Low Osmolar Contrast Media; ODM derived from: https://clinicaltrials.gov/show/NCT01563484

Screening Demographics GOAL Trial B-cell Lymphoma NCT02499003

- 9/20/21 - 1 form, 1 itemgroup, 6 items, 1 language

Itemgroup: Demographics

NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma Study part: Demographics (Screening) Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Screening Biopsy GOAL Trial B-cell Lymphoma NCT02499003

- 9/20/21 - 1 form, 3 itemgroups, 22 items, 1 language

Itemgroups: Admininstrative data, Bone marrow biopsy, Biopsy Tumor

NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Screening Serology GOAL Trial B-cell Lymphoma NCT02499003

- 9/20/21 - 1 form, 1 itemgroup, 8 items, 1 language

Itemgroup: Serology Viral

NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma Visit: Screening. Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Biopsy GOAL Trial B-cell Lymphoma NCT02499003

- 9/20/21 - 1 form, 1 itemgroup, 13 items, 1 language

Itemgroup: Biopsy

NCT02499003 The GOAL Trial: Rescue Treatment With the Monoclonal Anti CD20-antibody Obinutuzumab (GA101) in Combination With Pixantrone for the Treatment of Patients With Relapsed Aggressive B-cell Lymphoma. Visit: End of Treatment. Source: Prof. Dr. med. Georg Heß Universitätsmedizin Mainz

Eligibility Lymphoma NCT02056548

- 9/20/21 - 1 form, 2 itemgroups, 12 items, 1 language

Itemgroups: Inclusion Criteria, Exclusion Criteria

Hepatitis B Virus Reactivation After Withdrawal of Preemptive Antiviral Therapy in Hematologic Malignancy; ODM derived from: https://clinicaltrials.gov/show/NCT02056548

Eligibility Lymphoma NCT02392039

- 9/20/21 - 1 form, 2 itemgroups, 11 items, 1 language

Itemgroups: Inclusion Criteria, Exclusion Criteria

Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT02392039

Eligibility Carcinoma NCT01061645

- 9/20/21 - 1 form, 2 itemgroups, 15 items, 1 language

Itemgroups: Inclusion Criteria, Exclusion Criteria

Study of MOC31-PE in Antigen Positive Carcinomas; ODM derived from: https://clinicaltrials.gov/show/NCT01061645

Eligibility Renal Cell Carcinoma NCT00610389

- 9/20/21 - 1 form, 2 itemgroups, 11 items, 1 language

Itemgroups: Inclusion Criteria, Exclusion Criteria

Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors; ODM derived from: https://clinicaltrials.gov/show/NCT00610389

Topotecan (HycamtinTM) with Carboplatin as First-Line Chemotherapy in Patients with Ovarian Cancer; 104864/612 - Baseline

- 9/17/21 - 1 form, 19 itemgroups, 80 items, 1 language

Itemgroups: Administrative documentation, Assessment Date, Demography, Menopausal Status, Medical History, Symptoms, Study Start Date, Concomitant Agent, ECOG performance status, Personal history of malignant neoplasm, unspecified, Ovarian Carcinoma, Histology, Ovarian Carcinoma, Operative Surgical Procedures, Tumor stage, Tumor Markers, Physical Examination, Lower abdomen, X-Ray Computed Tomography, Plain x-ray, Electrocardiography, Questionnaires, Quality of life, Receptor

Study ID: 104864/612 Clinical Study ID: 104864/612 Study Title: A Prospective, Open Label Phase II Study to Evaluate the Efficacy and Safety of Topotecan (HycamtinTM) in Combination with Carboplatin as First-line Chemotherapy in Patients with Ovarian Cancer Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: N/A Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Topotecan Trade Name: HycamtinTM Study Indication: Ovarian Cancer

Effect of casoptiant on cardiac conduction as compared to placebo and moxifloxacin 103447 - Eligibility Question

- 9/17/21 - 1 form, 4 itemgroups, 26 items, 1 language

Itemgroups: Administrative, Eligibility Question, Inclusion Criteria, Exclusion Criteria

Study ID: 103447 Clinical Study ID: NKV103447 Study Title:A study to evaluate the effect of casoptiant on cardiac conduction as assessed by 12-lead electrocardiogram as compared to placebo and moxifloxacin Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Sponsor: GlaxoSmithKline Phase: Phase 1 Study Recruitment Status: Completed Generic Name: casopitant Trade Name: Rezonic,Zunrisa; Zunrisa,Rezonic Study Indication: Nausea and Vomiting, Chemotherapy-Induced

Please use this form for feedback, questions and suggestions for improvements.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.